10-K: BioAge Labs Reports Positive BGE-102 Phase 1 Data, Funds Operations Through 2029

BioAge Labs, Inc. announced positive interim Phase 1 data for its lead program BGE-102, demonstrating significant hsCRP reduction, and confirmed sufficient capital to fund operations through 2029.

Summary

• BioAge Labs is a clinical-stage biopharmaceutical company focused on developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging.
• The lead program, BGE-102, a novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor, showed positive interim Phase 1 data.
• In obese participants with elevated hsCRP, BGE-102 demonstrated an 86% median reduction in hsCRP at Day 14, with 93% achieving levels below 2 mg/L.
• This hsCRP reduction is comparable to injectable anti-IL-6 monoclonal antibodies but achieved with once-daily oral dosing.
• BGE-102 was well-tolerated in Single Ascending Dose (SAD) and initial Multiple Ascending Dose (MAD) cohorts, with a pharmacokinetic profile supporting once-daily oral dosing and high brain penetration.
• The company plans to advance BGE-102 in two therapeutic areas: atherosclerotic cardiovascular disease (ASCVD) risk reduction and diabetic macular edema (DME).
• A Phase 2a proof-of-concept trial for ASCVD risk reduction is planned for the first half of 2026, with results anticipated by year-end 2026.
• A Phase 1b/2a proof-of-concept trial for DME is planned for mid-2026, with results anticipated in mid-2027.
• Development of azelaprag, a former lead APJ agonist, was terminated in January 2025 due to observations of liver transaminitis in some Phase 2 trial patients.
• New novel apelin receptor APJ agonists are being developed for obesity, with plans to file the first Investigational New Drug applications (INDs) by year-end 2026.
• The company has ongoing target discovery collaborations with Eli Lilly and Company and Novartis Pharma AG.
• Net losses were $80.6 million for the year ended December 31, 2025, compared to $71.1 million for the year ended December 31, 2024.
• As of December 31, 2025, cash, cash equivalents, and marketable securities totaled $285.1 million, sufficient to fund operations and capital expenses through 2029.
• Collaboration revenue for the year ended December 31, 2025, was $9.0 million, primarily from the Novartis Agreement.
• Research and development expenses increased by $14.9 million to $73.9 million in 2025, driven by BGE-102 and other APJ programs, partially offset by the discontinuation of azelaprag development.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive. The strong interim Phase 1 data for BGE-102, particularly its oral dosing and significant hsCRP reduction, coupled with a solid cash runway through 2029 and strategic collaborations, are significant positives. While the discontinuation of azelaprag is a setback, the company's pivot to new APJ agonists and resolution of the securities litigation mitigate some concerns, indicating a focused and resilient development strategy despite ongoing losses inherent to a clinical-stage biopharma.

Positives

• BGE-102 demonstrated an 86% median reduction in hsCRP at Day 14 in obese participants with elevated cardiovascular risk, with 93% achieving clinically significant levels below 2 mg/L.
• BGE-102 showed a pharmacokinetic profile supporting once-daily oral dosing, strong target engagement, and high brain penetration, differentiating it from injectable competitors.
• Preclinical data for oral BGE-102 in DME models showed dose-dependent preservation of retinal vascular integrity and near-complete protection from vascular leakage.
• Oral BGE-102 improved insulin sensitivity in diet-induced obese mice to a degree comparable to semaglutide, suggesting potential for addressing metabolic drivers of DME.
• New apelin receptor APJ agonists are being advanced for obesity, with preclinical models showing potential to more than double weight loss induced by GLP-1R agonists while restoring healthy body composition and improving muscle function.
• The company has secured collaborations with major pharmaceutical companies, Eli Lilly and Company and Novartis Pharma AG, for target discovery and platform-derived programs.
• The Novartis Agreement provides upfront payments, research funding up to $20.0 million, and potential future long-term research, development, and commercial milestones up to $530.0 million.
• Cash, cash equivalents, and marketable securities of $285.1 million as of December 31, 2025, are estimated to fund operations through 2029, providing a solid liquidity runway.
• The securities class action complaint filed on January 7, 2025, was dismissed with prejudice on March 2, 2026, resolving a significant legal overhang.

Negatives

• The company incurred significant operating losses of $80.6 million in 2025 and $71.1 million in 2024, and expects to incur significant losses for the foreseeable future.
• Development of the former lead product candidate, azelaprag, was terminated in January 2025 due to observations of liver transaminitis in some patients during a Phase 2 clinical trial.
• The company has a limited operating history and no products approved for commercial sale, making it difficult for investors to evaluate its likelihood of success.
• Drug development is a lengthy, expensive, and uncertain process, with a high rate of failure, particularly in earlier stages.
• The company is substantially dependent on its ability to identify and develop future product candidates, and there is no assurance that BGE-102 or any future candidates will achieve regulatory approval or commercial viability.
• The market value of voting and non-voting common equity held by non-affiliates was approximately $112.7 million as of June 30, 2025, indicating a relatively small market capitalization for a clinical-stage biopharma.

Risks

• The company is a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale, making it difficult for investors to evaluate its business, likelihood of success, and viability.
• Significant operating losses have been incurred since inception, and substantial losses are expected for the foreseeable future, with no guarantee of achieving or sustaining profitability.
• Substantial additional capital will be required to finance operations and achieve goals; inability to raise capital on acceptable terms could force delays or elimination of research/development programs.
• Failure to advance, receive regulatory approval for, or successfully commercialize BGE-102 or future product candidates, or significant delays, would materially harm the business.
• Drug development is lengthy and expensive, clinical testing outcomes are uncertain, and earlier study results may not predict future trial results, potentially leading to additional costs or delays.
• Developing future product candidates in combination with other therapies exposes the company to additional risks, including regulatory revocation of combination therapy approvals or supply issues.
• Expanding development, clinical, and regulatory capabilities may lead to difficulties in managing growth and disrupt operations.
• Quarterly and annual operating results may fluctuate significantly or fall below expectations, causing stock price volatility or decline.
• Negative results or publicity for one drug in ASCVD risk reduction, DME, or obesity could substantially impact all drugs and product candidates in those areas.
• The company is subject to securities litigation, which is expensive and can divert management attention.
• Previous material weaknesses in internal control over financial reporting, though remediated, could recur or new deficiencies could arise, leading to financial misstatements or reporting failures.
• Reliance on third parties to conduct clinical trials and perform research/preclinical studies carries risks of unsatisfactory performance, non-compliance, or missed deadlines, delaying development programs or regulatory approval.
• The complex manufacture of pharmaceutical products by third-party manufacturers may encounter production difficulties, delaying or halting supply for clinical trials or commercial sale.
• Inability to protect intellectual property rights, including insufficient patent term extension, could harm the business and competitive position.
• Changes in U.S. and ex-U.S. patent laws could diminish the value of patents, impairing the ability to protect product candidates.
• Inadequate protection of trademarks and trade names could hinder name recognition and adversely affect the business.
• Intellectual property rights may not address all potential threats, and competitors could develop similar products not covered by existing patents.
• Rights to develop and commercialize products are subject to license agreements, and breaches could materially affect commercialization efforts.
• Third-party claims of intellectual property infringement may prevent or delay product discovery and development efforts.
• Inability to protect the confidentiality of trade secrets would harm the business and competitive position.
• Disruptions at the FDA, SEC, and other government agencies due to funding shortages, global health concerns, or new administration initiatives could hinder regulatory processes.
• Existing, recently enacted, and future legislation (e.g., Inflation Reduction Act) may increase the difficulty and cost of obtaining regulatory approval and commercializing products, and decrease prices.
• Uncertainty regarding insurance coverage and reimbursement for newly approved products could limit marketability and revenue generation.
• Operations and relationships with healthcare providers are subject to anti-bribery, anti-kickback, fraud and abuse, and transparency laws, exposing the company to enforcement actions and penalties.
• Adverse side effects or safety risks associated with BGE-102 or future product candidates could delay/preclude approval, suspend trials, limit commercial profile, or lead to negative consequences post-approval.
• Conducting clinical trials outside the U.S. may lead to non-acceptance of data by the FDA and additional delays/expenses.
• Subject to U.S. and foreign export/import controls, sanctions, embargoes, anti-corruption, and anti-money laundering laws, with compliance potentially impairing competitiveness.
• Anti-takeover provisions in charter documents and Delaware law could prevent or delay an acquisition or make it difficult for stockholders to replace management.
• The market price of common stock is likely to be highly volatile, and investors could lose all or part of their investment.
• No current intention to pay dividends, making stock appreciation the sole return on investment.
• Lack of analyst coverage or adverse/misleading analyst opinions could cause stock price and trading volume to decline.
• Sale of a substantial number of common stock shares could cause the price to decline.
• Current in-person operations in Emeryville, CA, and reliance on third parties make the company vulnerable to natural disasters, terrorist activity, pandemics, and geopolitical actions.
• Unstable market and economic conditions, including inflation, interest rates, and financial services industry disruptions, could adversely affect business operations and financial condition.

Future Outlook

The company anticipates full Phase 1 SAD/MAD clinical trial results for BGE-102 in the first half of 2026. A Phase 2a proof-of-concept trial for ASCVD risk reduction is planned for initiation in the first half of 2026, with results expected by year-end 2026. A Phase 1b/2a proof-of-concept trial for DME is planned to begin in mid-2026, with results anticipated in mid-2027. The company intends to file the first Investigational New Drug applications (INDs) for an APJ program by year-end 2026. Existing cash, cash equivalents, and marketable securities are estimated to fund operations and capital expenses through 2029. The company expects to continue incurring significant operating losses and increasing research and development expenses as it advances its pipeline and expands operations.

Management Comments

• "We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging."
• "Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging."
• "BGE-102 was well-tolerated in Single Ascending Dose (SAD) and initial Multiple Ascending Dose (MAD) cohorts, with a pharmacokinetic profile supporting once-daily oral dosing, strong target engagement and high brain penetration."
• "In obese participants with elevated hsCRP, BGE-102 demonstrated an 86% median reduction in hsCRP at Day 14, with 93% of participants achieving hsCRP levels below 2 mg/L."
• "This level of hsCRP reduction is comparable to injectable anti-IL-6 monoclonal antibodies in clinical development for ASCVD, but achieved with once-daily oral dosing."
• "We anticipate full Phase 1 SAD / MAD clinical trial results in the first half of 2026."
• "We plan to initiate a Phase 2a proof-of-concept trial in patients with obesity and elevated hsCRP in the first half of 2026, with results anticipated by 2026 year end."
• "We plan to initiate a Phase 1b/2a proof-of-concept trial in DME in mid-2026 with results anticipated in mid-2027."
• "We intend to file the first Investigational New Drug applications (INDs) for an APJ program by 2026 year end."
• "We believe the results of the azelaprag Phase 1 trials demonstrate the potential of apelin receptor APJ agonists; therefore, we are advancing distinct, orally available apelin receptor APJ agonists as a novel exercise mimetic approach for the treatment of obesity."
• "Our goal is to develop a focused portfolio of therapies for cardiometabolic disease by targeting the biology of human aging."
• "We believe that APJ agonism has the potential to transform the treatment of obesity by increasing weight loss quantity and quality, including improved body composition and tolerability."
• "We estimate that our existing cash, cash equivalents and marketable securities as of the filing date of this Annual Report will be sufficient to fund our operations and capital expenses through 2029."

Industry Context

StockSavvy.ai notes that BioAge Labs operates in the highly competitive and rapidly evolving biopharmaceutical industry, specifically targeting age-related metabolic diseases. The focus on NLRP3 inhibition for cardiometabolic disease and DME, and APJ agonism for obesity, positions the company in areas with significant unmet medical needs and large market opportunities. The reported 86% median hsCRP reduction for BGE-102 is a strong signal, potentially offering a best-in-class oral alternative to injectable anti-IL-6 monoclonal antibodies in ASCVD, which could be a significant commercial advantage given patient preference for oral medications. The discontinuation of azelaprag highlights the inherent risks of drug development, even with promising early-stage data. The pursuit of novel APJ agonists for obesity, particularly those that enhance weight loss quality and body composition, aligns with the industry's shift towards more holistic obesity treatments beyond just weight reduction, especially in the context of the booming GLP-1R agonist market. Collaborations with major players like Eli Lilly and Novartis validate the company's platform and target discovery approach.

Comparison to Industry Standards

• BGE-102's 86% median hsCRP reduction in obese participants with elevated cardiovascular risk is comparable to injectable anti-IL-6 monoclonal antibodies in clinical development for ASCVD, such as canakinumab (CANTOS trial), but achieved with once-daily oral dosing, offering a potential convenience advantage.
• The 93% of BGE-102 participants achieving hsCRP levels below 2 mg/L is a clinically significant threshold, associated with a 25% reduction in major adverse cardiovascular events in the CANTOS trial.
• In a preclinical model of DME, oral BGE-102 demonstrated near-complete protection from vascular leakage and up to 90% preservation of microvascular integrity, suggesting a potentially broader effect than intravitreal anti-VEGF therapies (e.g., Eylea, Lucentis) which face significant refractory populations (approx. 45%).
• Preclinical APJ agonism demonstrated ability to more than double weight loss induced by a GLP-1R agonist (e.g., semaglutide, tirzepatide) while restoring healthy body composition and improving muscle function, addressing a key limitation of current incretin-based obesity therapeutics where up to 50% of weight loss can be lean muscle mass.
• The modest clinical efficacy of approved intravitreal complement inhibitors for geographic atrophy (e.g., pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay), slowing lesion growth by 15-20%) suggests a substantial unmet need that oral NLRP3 inhibition, with its broader mechanistic activity, could potentially address.

Corporate Governance

Legal Proceedings

• On January 7, 2025, a putative securities class action complaint was filed against the company and certain officers/directors in the U.S. District Court for the Northern District of California, alleging violations of Section 11 and Section 15 of the Securities Act of 1933 related to azelaprag disclosures.
• An amended complaint was filed on June 2, 2025.
• On October 30, 2025, the Court granted defendants' motion to dismiss without prejudice.
• On November 20, 2025, a further amended complaint was filed.
• On March 2, 2026, the Court granted defendants' further motion to dismiss with prejudice, requiring plaintiff to file any notice of appeal within 30 days after entry of judgment.

Related Party Transactions

• In September 2024, in a concurrent private placement with Sofinnova Venture Partners, XI, L.P., an existing stockholder, the company issued and sold 588,888 shares of its common stock at $18.00 per share for net proceeds of $9.9 million.

Stakeholder Impact

• **Shareholders**: Potential for increased value from positive clinical trial results for BGE-102 and future pipeline candidates, but also risk of dilution from future capital raises and continued operating losses. Resolution of securities litigation is positive.
• **Employees**: Continued investment in research and development, and expansion of capabilities, suggests job stability and growth opportunities. Stock-based compensation plans are in place to attract and retain talent.
• **Customers/Patients**: Potential for novel oral therapies for significant unmet needs in cardiometabolic disease, DME, and obesity, offering improved convenience and efficacy profiles compared to existing treatments.
• **Collaborators (Novartis, Eli Lilly, JiKang Therapeutics)**: Ongoing and new collaborations indicate continued partnership opportunities and shared development efforts, potentially leading to broader market reach and accelerated development.
• **Creditors**: The company has a Term Loan with $2.0 million outstanding as of December 31, 2025, maturing April 1, 2026. The recent capital raises and cash position provide confidence in repayment.

Next Steps

• Anticipate full Phase 1 SAD/MAD clinical trial results for BGE-102 in the first half of 2026.
• Initiate a Phase 2a proof-of-concept trial for BGE-102 in patients with obesity and elevated hsCRP in the first half of 2026, with results anticipated by year-end 2026.
• Initiate a Phase 1b/2a proof-of-concept trial for BGE-102 in patients with DME in mid-2026, with results anticipated in mid-2027.
• File the first Investigational New Drug applications (INDs) for an APJ program by year-end 2026.
• Continue advancing earlier stage platform-derived programs in collaboration with Eli Lilly and Company.
• Continue the ongoing target discovery collaboration with Novartis Pharma AG.
• Expand the pipeline over time, both internally and potentially through additional partnerships.
• Monitor and adapt to evolving regulatory guidance and enforcement landscape regarding data transfers and privacy laws.
• Manage and mitigate cybersecurity risks, including those presented by third-party service providers.

Key Dates

Recommendation

The positive interim Phase 1 data for BGE-102 is encouraging and suggests significant potential in large markets like ASCVD and DME, which could drive future growth. The company's strong cash position, sufficient to fund operations through 2029, provides a substantial runway for continued development. However, the company remains clinical-stage with no approved products, continues to incur significant losses, and experienced a setback with the termination of azelaprag. While the dismissal of the securities lawsuit is a positive, the inherent risks of biopharmaceutical development, including clinical trial failures and the need for substantial future capital, warrant a 'hold' recommendation. Investors should monitor upcoming clinical trial results for BGE-102 and progress on new APJ agonists for further clarity on the company's long-term prospects.

Keywords

Biopharmaceutical, Clinical-stage, Aging biology, Metabolic diseases, BGE-102, NLRP3 inhibitor, Cardiovascular disease, Atherosclerotic cardiovascular disease (ASCVD), Diabetic macular edema (DME), hsCRP reduction, APJ agonists, Obesity, Drug development, Clinical trials, Regulatory approval, SEC filing, 10-K, Biotech investment